Bull case
The bull case prices DD at 5x on FY1 earnings, assuming continued execution and no meaningful deceleration in the core business.
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Three scenarios for where DD stock could go
The bull case prices DD at 5x on FY1 earnings, assuming continued execution and no meaningful deceleration in the core business.
At 4x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
If investor confidence fades or macro conditions deteriorate, a 18x multiple contraction could push DD down roughly 88% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.

DuPont is a specialty chemicals company that develops high-performance materials and solutions for electronics, transportation, and industrial applications. It generates revenue primarily through three segments: Electronics & Industrial (~40% of sales), Mobility & Materials (~30%), and Water & Protection (~30%). The company's competitive advantage lies in its deep R&D capabilities, extensive patent portfolio, and long-standing customer relationships in technically demanding industries.
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $1.12/$0.45 | +151.7% | $3.3B/$3.2B | +0.5% |
| Q4 2025 | $1.09/$0.47 | +134.1% | $3.1B/$2.9B | +5.9% |
| Q1 2026 | $0.46/$0.43 | +7.0% | $1.7B/$1.7B | +0.3% |
| Q2 2026 | $0.55/$0.49 | +12.7% | $1.7B/$1.7B | +0.9% |
DD beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest annual revenue by segment or product family
Latest annual revenue by reported region
Tap, hover, or focus a slice to inspect segment detail.
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Fair value est. $44 — implies -6.9% from today's price.
| Metric | DD | S&P 500 | Basic Materials | 5Y Avg DD |
|---|---|---|---|---|
| Forward PE | 20.0x | 18.8x | 14.9x+35% | — |
| Trailing PE | -25.6x | 24.4x-205% | 23.6x-209% | 14.6x-275% |
| PEG Ratio | — | 1.66x | 1.23x | — |
| EV/EBITDA | 14.6x | 15.2x | 11.0x+32% | 8.2x+77% |
| Price/FCF | 18.1x | 20.7x-12% | 29.0x-37% | 12.2x+49% |
| Price/Sales | 2.9x | 3.1x | 1.9x+52% | 1.5x+95% |
| Dividend Yield | 2.99% | 1.91% | 1.41% | 4.15% |
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolDD generates $1.1B in free cash flow at a 11.4% margin — returns 5.5% of market cap to shareholders annually.
Revenue, margins, and cash generation
ROIC, leverage, and debt serviceability
~2.2 years to full repayment at current FCF run-rate
How capital is returned to owners
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageKey factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
Deep dive into DuPont de Nemours's financial health indicates potential concerns that investors should review before committing capital.
Despite strong quarterly results, operational execution risks remain as the company navigates complex industrial and healthcare markets.
DuPont operates in highly competitive segments like healthcare and industrial solutions, where innovation and pricing pressures could impact margins.
As a producer of engineered products for critical industries, DuPont faces regulatory risks that could affect operations and profitability.
While DuPont invests in advanced science and technology, rapid technological changes could render some of its solutions obsolete.
DuPont's broad industrial exposure makes it vulnerable to economic downturns, impacting demand for its products.
Although DuPont raised its financial guidance, achieving these targets depends on sustained commercial and operational execution.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
DuPont provides leading engineered products and solutions across healthcare, water, and industrial segments, driving innovation and market leadership.
The company's robust financial health and competitive advantages position it well for long-term growth and stability.
Successful cost-saving measures and operational efficiencies are expected to improve margins and support upside potential.
DuPont's commitment to advanced science and technology fuels its ability to address current challenges and shape future markets.
Modest improvements in cyclical markets could enhance DuPont's revenue and profitability in the near term.
Strategic share repurchases are likely to drive earnings per share growth and shareholder value.
Recent robust quarterly results have propelled the stock to new highs, validating the bullish investment thesis.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
DD DD DuPont de Nemours, Inc. | $19.5B | 20.0x | -12.0% | -0.3% | Buy | +18.2% |
DOW DOW Dow Inc. | $22.8B | 10.0x | +4.6% | -7.0% | Hold | +24.0% |
LYB LYB LyondellBasell Industries N.V. | $19.4B | 6.4x | +2.9% | -3.4% | Hold | +33.5% |
EMN EMN Eastman Chemical Company | $8.3B | 11.4x | +0.1% | 4.6% | Buy | +10.2% |
CE CE Celanese Corporation | $5.7B | 8.3x | +2.7% | -10.8% | Hold | +28.2% |
HUN HUN Huntsman Corporation | $2.1B | — | +1.7% | -5.7% | Hold | +14.3% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
DD returns 5.5% total yield, led by a 2.99% dividend. Buybacks add another 2.6%.
Yield, cadence, and growth quality
How much per-share support comes from repurchases
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $0.40 | — | — | — |
| 2025 | $0.71 | +12.4% | 3.0% | 6.5% |
| 2024 | $0.64 | +5.6% | 3.7% | 8.5% |
| 2023 | $0.60 | +9.1% | 13.8% | 18.3% |
| 2022 | $0.55 | +10.0% | 30.5% | 35.0% |
Common questions answered from live analyst data and company financials.
DuPont de Nemours, Inc. (DD) is rated Buy by Wall Street analysts as of 2026. Of 41 analysts covering the stock, 24 rate it Buy or Strong Buy, 16 rate it Hold, and 1 rate it Sell or Strong Sell. The consensus 12-month price target is $56, implying +18.2% from the current price of $48. The bear case scenario is $6 and the bull case is $12.
The Wall Street consensus price target for DD is $56 based on 41 analyst estimates. The high-end target is $60 (+25.8% from today), and the low-end target is $52 (+9.0%). The base case model target is $9.
DD trades at 20.0x times forward earnings. The stock currently trades at a discount to the broader market. Based on current multiples versus the peer group, the relative model signals fair versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
The primary risks for DD in 2026 are: (1) Financial Health Risks — Deep dive into DuPont de Nemours's financial health indicates potential concerns that investors should review before committing capital. (2) Market Competition — DuPont operates in highly competitive segments like healthcare and industrial solutions, where innovation and pricing pressures could impact margins. (3) Economic Sensitivity — DuPont's broad industrial exposure makes it vulnerable to economic downturns, impacting demand for its products. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
Analyst consensus estimates DD will report consensus revenue of $8.5B (-12.0% year-over-year) and EPS of $0.74 (+1150.1% year-over-year) for the upcoming fiscal year. The following year, analysts project $7.7B in revenue.
DuPont de Nemours, Inc. is expected to report its next earnings on approximately 2026-08-04. Consensus expects EPS of $0.58 and revenue of $1.8B. Over recent quarters, DD has beaten EPS estimates 100% of the time.
DuPont de Nemours, Inc. (DD) generated $1.1B in free cash flow over the trailing twelve months — a free cash flow margin of 11.4%. DD returns capital to shareholders through dividends (3.0% yield) and share repurchases ($500M TTM).